bictegravir–emtricitabine–tenofovir alafenamide
Biktarvy
Pharmaceutical company: Gilead Sciences
NEW AVAILABLE FORM
Tablets: 30 mg bictegravir; 120 mg emtricitabine; 15 mg tenofovir alafenamide
NEW INDICATION & DOSAGE
HIV-1 infection in children weighing 14 to less than 25 kg who have no antiretroviral treatment history, or to replace current antiretroviral regimen in children who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to individual components
Children weighing 14 to less than 25 kg: 1 tablet of 30 mg bictegravir; 120 mg emtricitabine; 15 mg tenofovir alafenamide PO daily.
Released: January 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
dupilumab
Dupixent
Pharmaceutical company: Sanofi and Regeneron Pharmaceuticals
NEW INDICATION & DOSAGE
Add-on maintenance treatment of moderate to severe eosinophilic or oral corticosteroid-dependent asthma
Children ages 6 to 11 weighing 30 kg or more: 200 mg subcut every other week.
Children ages 6 to 11 weighing 15 to less than 30 mg: 100 mg subcut every other week or 300 mg every 4 weeks.
Released: January 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
ferric carboxymaltose
Injectafer
Pharmaceutical company: Daiichi Sankyo
NEW INDICATION & DOSAGE
Iron deficiency anemia in patients intolerant to or who have had unsatisfactory response to oral iron
Children age 1 and older weighing 50 kg or more: 750 mg IV on day 1; repeat dose after at least 7 days. May repeat course of therapy if anemia recurs. Maximum cumulative dose is 1,500 mg per course.
Children age 1 and older weighing less than 50 kg: 15 mg/kg IV on day 1; repeat dose after at least 7 days. May repeat course of therapy if anemia recurs.
Released: January 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
lacosamide
Vimpat
Pharmaceutical company: UCB, Inc.
NEW INDICATION & DOSAGE
Monotherapy for partial-onset seizures
Children age 1 month and older weighing 6 to less than 11 kg: Initially, 1 mg/kg PO or IV b.i.d. Then increase by 1 mg/kg b.i.d. at weekly intervals to recommended dose of 3 to 6 mg/kg b.i.d.
Children age 1 month and older weighing less than 6 kg: Initially, 0.66 mg/kg IV t.i.d. Then increase by 0.66 mg/kg IV t.i.d. at weekly intervals to recommended IV dose of 2.5 to 5 mg/kg t.i.d. Or initially, 1 mg/kg PO b.i.d. Then increase by 1 mg/kg b.i.d. at weekly intervals to recommended PO dose of 3.75 to 7.5 mg/kg b.i.d.
Released: January 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
pilocarpine hydrochloride (ophthalmic)
Vuity
Pharmaceutical company: Allergan
NEW AVAILABLE FORM
Ophthalmic solution: 1.25%
INDICATION & DOSAGE
Presbyopia (Vuity)
Adults: Instill 1 drop of 1.25% solution in each eye once daily.
Released: January 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer